Bio-reductive Co(iii)-doxorubicin complex for cancer cell-selective delivery of doxorubicin and potent anticancer activity.

ABSTRACT: The utility of bio-reductive prodrugs in cancer research has emerged as an attractive strategy. We synthesized and characterized a couple of cobalt(iii)-Schiff base complexes of general molecular formula Co(L¹)(L²) [Co(iii)-dione] and Co(L¹)(dox) [Co(iii)-dox], where L¹ and L² are N,N-(ethane-1,2-diyl)bis(1-(pyridine-2-yl)methanimine) and 1-phenyl-1,3-butanedione, and dox = doxorubicin, as bio-reductive prodrugs. UV-vis and fluorescence spectroscopic assays confirmed the reductive release of doxorubicin from the complex [Co(iii)-dox] in a GSH-dependent manner under physiological conditions, showing its potential for in vitro drug release. The rate of doxorubicin release was found to be 8.20 min

SUBMITTER: Wahengbam S 

PROVIDER: S-EPMC12409735 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature